FL118, acting as a ‘molecular glue degrader’, binds to, dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c‐Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy-Reference-Cited by-同舟云学术

FL118, acting as a ‘molecular glue degrader’, binds to, dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c‐Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy

Published:2022-05 Issue:5 Volume:12 Page:
ISSN:2001-1326
Container-title:Clinical and Translational Medicine
language:en
Short-container-title:Clinical & Translational Med

Author:

Ling Xiang¹²,Wu Wenjie¹²,Aljahdali Ieman A. M.¹³,Liao Jianqun²,Santha Sreevidya²,Fountzilas Christos⁴⁵,Boland Patrick M.⁴,Li Fengzhi¹⁵^ORCID

Affiliation:

1. Department of Pharmacology & Therapeutics Roswell Park Comprehensive Cancer Center Buffalo New York USA

2. Canget BioTekpharma LLC Buffalo New York USA

3. Department of Cellular & Molecular Biology Roswell Park Comprehensive Cancer Center Buffalo New York USA

4. Department of Medicine Roswell Park Comprehensive Cancer Center Buffalo New York USA

5. Developmental Therapeutics (DT) Program Roswell Park Comprehensive Cancer Center Buffalo New York USA

Funder

Pancreatic Cancer Action Network

National Institutes of Health

National Cancer Institute

U.S. Department of Defense

Publisher

Wiley

Subject

Molecular Medicine,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ctm2.881

Reference86 articles.

1. Cancer Statistics, 2021

2. Control of apoptosis and mitotic spindle checkpoint by survivin

3. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. E3 ubiquitin ligases and deubiquitinases in colorectal cancer: Emerging molecular insights and therapeutic opportunities;Biochimica et Biophysica Acta (BBA) - Molecular Cell Research;2024-12

2. FL118: A potential bladder cancer therapeutic compound targeting H2A.X identified through library screening;Bioorganic Chemistry;2024-12

3. Development of natural product-based targeted protein degraders as anticancer agents;Bioorganic Chemistry;2024-12

4. Survivin (BIRC5): Implications in cancer therapy;Life Sciences;2024-08

5. Clinically and orally compatible formulation-manufactured DDX5 (p68)-targeting molecular glue FL118 products exhibit low toxicity but high efficacy against human cancer;Journal of Pharmaceutical Analysis;2024-05